Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiichi Torimoto

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Endocrine Journal|October 3, 2014
Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case reportAkira Kurozumi, Yosuke Okada, Tadashi Arao, et al.
Journal of the American Heart Association|November 29, 2022
Endoplasmic Reticulum Chemical Chaperone 3-Hydroxy-2-Naphthoic Acid Reduces Angiotensin II-Induced Vascular Remodeling and Hypertension In Vivo and Protein Synthesis In VitroStephanie Cicalese, Keiichi Torimoto, Keisuke Okuno, et al.
Diabetes Technology & Therapeutics|June 19, 2019
Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 InhibitorAkira Kurozumi, Yosuke Okada, Mototsugu Shimokawa, et al.
Journal of Molecular and Cellular Cardiology|February 3, 2023
Smooth muscle angiotensin II type 1A receptor is required for abdominal aortic aneurysm formation induced by angiotensin II plus β-aminopropionitrileKeisuke Okuno, Keiichi Torimoto, Stephanie M Cicalese, et al.
Endocrine Journal|January 15, 2014
Glucose variability before and after treatment of a patient with Graves' disease complicated by diabetes mellitus: assessment by continuous glucose monitoringKeiichi Torimoto, Yosuke Okada, Tadashi Arao, et al.
Cardiovascular Diabetology|June 15, 2020
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trialAtsushi Tanaka, Michio Shimabukuro, Yosuke Okada, et al.
Jvs-Vascular Science|January 15, 2025
Glucose transporter 1 in vascular smooth muscle cells is dispensable for abdominal aortic aneurysm induced by angiotensin IIKeiichi Torimoto, Hymavathi Reddy Vari, Yuki Nakayama, et al.
Endocrinology, Diabetes & Metabolism Case Reports|June 3, 2016
Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case reportAkira Kurozumi, Yosuke Okada, Tadashi Arao, et al.
Journal of UOEH|December 3, 2020
Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes MellitusSatomi Sonoda, Yosuke Okada, Keiichi Torimoto, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 12, 2023
Infused juice concentrate of Japanese plum Prunus mume attenuates inflammatory vascular remodeling in a mouse model of hypertension induced by angiotensin IIKeisuke Okuno, Keiichi Torimoto, Ryohei Kuroda, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Endocrine Journal|October 3, 2014
Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case reportAkira Kurozumi, Yosuke Okada, Tadashi Arao, et al.
Journal of the American Heart Association|November 29, 2022
Endoplasmic Reticulum Chemical Chaperone 3-Hydroxy-2-Naphthoic Acid Reduces Angiotensin II-Induced Vascular Remodeling and Hypertension In Vivo and Protein Synthesis In VitroStephanie Cicalese, Keiichi Torimoto, Keisuke Okuno, et al.
Diabetes Technology & Therapeutics|June 19, 2019
Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 InhibitorAkira Kurozumi, Yosuke Okada, Mototsugu Shimokawa, et al.
Journal of Molecular and Cellular Cardiology|February 3, 2023
Smooth muscle angiotensin II type 1A receptor is required for abdominal aortic aneurysm formation induced by angiotensin II plus β-aminopropionitrileKeisuke Okuno, Keiichi Torimoto, Stephanie M Cicalese, et al.
Endocrine Journal|January 15, 2014
Glucose variability before and after treatment of a patient with Graves' disease complicated by diabetes mellitus: assessment by continuous glucose monitoringKeiichi Torimoto, Yosuke Okada, Tadashi Arao, et al.
Cardiovascular Diabetology|June 15, 2020
Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trialAtsushi Tanaka, Michio Shimabukuro, Yosuke Okada, et al.
Jvs-Vascular Science|January 15, 2025
Glucose transporter 1 in vascular smooth muscle cells is dispensable for abdominal aortic aneurysm induced by angiotensin IIKeiichi Torimoto, Hymavathi Reddy Vari, Yuki Nakayama, et al.
Endocrinology, Diabetes & Metabolism Case Reports|June 3, 2016
Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case reportAkira Kurozumi, Yosuke Okada, Tadashi Arao, et al.
Journal of UOEH|December 3, 2020
Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes MellitusSatomi Sonoda, Yosuke Okada, Keiichi Torimoto, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 12, 2023
Infused juice concentrate of Japanese plum Prunus mume attenuates inflammatory vascular remodeling in a mouse model of hypertension induced by angiotensin IIKeisuke Okuno, Keiichi Torimoto, Ryohei Kuroda, et al.
Pageof 8